Amy Bachrodt Sells 5,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) SVP Amy Bachrodt sold 5,000 shares of the stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $45.52, for a total value of $227,600.00. Following the completion of the transaction, the senior vice president directly owned 12,965 shares of the company’s stock, valued at approximately $590,166.80. The trade was a 27.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Amy Bachrodt also recently made the following trade(s):

• On Friday, January 2nd, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $39.15, for a total transaction of $195,750.00.
• On Monday, December 29th, Amy Bachrodt sold 10,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.58, for a total value of $405,800.00.
• On Tuesday, December 30th, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.08, for a total transaction of $200,400.00.

Maze Therapeutics Trading Up 1.7%

Shares of Maze Therapeutics stock opened at $45.34 on Wednesday. The stock has a 50-day moving average price of $40.36 and a 200 day moving average price of $28.57. The company has a market cap of $2.18 billion and a P/E ratio of -2.17. Maze Therapeutics, Inc. has a 1 year low of $6.71 and a 1 year high of $47.36.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.08.

Institutional Investors Weigh In On Maze Therapeutics

A number of large investors have recently modified their holdings of the business. CWM LLC bought a new stake in shares of Maze Therapeutics during the second quarter worth about $28,000. GF Fund Management CO. LTD. bought a new stake in Maze Therapeutics in the fourth quarter valued at $39,000. Ameritas Investment Partners Inc. boosted its holdings in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after acquiring an additional 738 shares in the last quarter. Russell Investments Group Ltd. grew its position in Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after purchasing an additional 1,725 shares during the period. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Maze Therapeutics during the third quarter worth about $52,000.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a report on Thursday, January 22nd. Lifesci Capital upgraded shares of Maze Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. HC Wainwright increased their target price on shares of Maze Therapeutics from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, December 3rd. Wedbush boosted their price objective on Maze Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Finally, Guggenheim reiterated a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a report on Friday, December 19th. Three research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $44.50.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.